Letter to the Editor Re: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomized, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).
作者信息
Zhou F, Chen W, Ruan L
机构信息
Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People's Hospital, Jiujiang, Jiangxi Province, China.
Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People's Hospital, Jiujiang, Jiangxi Province, China.
出版信息
ESMO Open. 2025 Jul 15;10(8):105535. doi: 10.1016/j.esmoop.2025.105535.
Abstract
摘要
相似文献
1
Letter to the Editor Re: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomized, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).致编辑的信：关于晚期胆管癌的分子靶向维持治疗与标准治疗：一项国际、随机、对照、开放标签的III期伞式试验（SAFIR-ABC10-精准医学）
ESMO Open. 2025 Jul 15;10(8):105535. doi: 10.1016/j.esmoop.2025.105535.
2
Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).对关于以下内容的信件评论的回复：晚期胆管癌的分子靶向维持治疗与标准治疗的比较：一项国际、随机、对照、开放标签的III期伞式试验（SAFIR-ABC10-精准医学）
ESMO Open. 2025 Jul 18;10(8):105536. doi: 10.1016/j.esmoop.2025.105536.
3
Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).晚期胆管癌的分子靶向维持治疗与标准治疗对比：一项国际、随机、对照、开放标签的III期伞形试验（SAFIR-ABC10-精准医学）
ESMO Open. 2025 Apr 9;10(5):104540. doi: 10.1016/j.esmoop.2025.104540.
4
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.贝伐珠单抗联合厄洛替尼作为化疗敏感晚期胆囊癌和胆管癌的维持治疗（BEER BTC）：一项多中心、开放标签、随机、II 期临床试验。
J Clin Oncol. 2024 Sep 20;42(27):3218-3227. doi: 10.1200/JCO.23.02420. Epub 2024 Aug 5.
5
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).曲妥珠单抗多卡霉素用于经治的人表皮生长因子受体2阳性晚期或转移性乳腺癌：一项开放标签、随机、III期试验（郁金香试验）
J Clin Oncol. 2025 Feb 10;43(5):513-523. doi: 10.1200/JCO.24.00529. Epub 2024 Oct 23.
6
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
7
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.基于吉西他滨的晚期胆管癌化疗
Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2.
9
Interventions for managing medication-related osteonecrosis of the jaw.颌骨药物相关性骨坏死的管理干预措施。
Cochrane Database Syst Rev. 2017 Oct 6;10(10):CD012432. doi: 10.1002/14651858.CD012432.pub2.
10
Efficacy and safety of warming Yang and dredging intestines method in metastatic colon cancer maintenance.温阳通腑法在转移性结肠癌维持治疗中的疗效与安全性
World J Clin Oncol. 2025 Jun 24;16(6):105175. doi: 10.5306/wjco.v16.i6.105175.
本文引用的文献
1
Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).晚期胆管癌的分子靶向维持治疗与标准治疗对比：一项国际、随机、对照、开放标签的III期伞形试验（SAFIR-ABC10-精准医学）
ESMO Open. 2025 Apr 9;10(5):104540. doi: 10.1016/j.esmoop.2025.104540.
2
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.用于治疗FGFR2重排型肝内胆管癌的futibatinib
N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.
3
Design and analysis of umbrella trials: Where do we stand?伞形试验的设计与分析：我们目前的进展如何？
Front Med (Lausanne). 2022 Oct 12;9:1037439. doi: 10.3389/fmed.2022.1037439. eCollection 2022.
4
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring / Aberrations: A Phase I Dose-Expansion Study.富替替尼，一种不可逆的 FGFR1-4 抑制剂，用于携带/突变的晚期实体瘤患者：一项 I 期剂量扩展研究。
Cancer Discov. 2022 Feb;12(2):402-415. doi: 10.1158/2159-8290.CD-21-0697. Epub 2021 Sep 22.
Zotero 插件